ZVSAOTCPharmaceutical PreparationsFiscal year ends December 31
ZyVersa Therapeutics, Inc.
Financials through Q1 FY2026, quarter ended Mar 31, 2026Last filing: 10-Q on May 13, 2026
$0.05+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $388.60K
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$0.0918 (−65.67%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Mar 31, 2026
Valuation
- Market cap
- $388.60K
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$24.49M
- EPS, diluted
- -$3.32
- Book value per share
- -$1.74
- Diluted shares
- 8M
Five years at a glance
Fiscal years 2021 to 2025 and trailing twelve months, USD
Operating income
-$24.65M
Net income
-$24.49M
EPS, diluted
-$3.32
Reported periodTrailing twelve months